Aardvark Therapeutics AARD
NASDAQ AARD
$1.59 +0.22 (+16.06%)
At close: Nov 11, 2026 · 4:00 PM EST

Aardvark Therapeutics (AARD) Return on Assets [ROA] (2025 - 2026)

Updated

Aardvark Therapeutics (AARD) reported Return on Assets [ROA] of -77.64% for Q2 2026, down 53.68 percentage points from -23.96% a year earlier and down 12.88 percentage points from the prior quarter.

Analysis

Aardvark Therapeutics (AARD) Return on Assets [ROA] (2025 - 2026) Analysis & Trends

For FY2025, Aardvark Therapeutics posted Return on Assets [ROA] of -59.16%.

  • Per Business Quant data, the three quarters before Q2 2026 came in at -64.76% (Q1 2026), -45.99% (Q4 2025) and -34.73% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 19.00%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.08%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 7.32%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 1.87%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.36%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 9.80%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -7.67%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 2.00%
10 Aardvark Therapeutics 29.98 Mn -43.92 Mn - -77.63%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -77.63%
Mar 31, 2026 -64.79%
Dec 31, 2025 -45.93%
Sep 30, 2025 -34.69%
Jun 30, 2025 -24.07%
Mar 31, 2025 -23.60%
API Access

Aardvark Therapeutics Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=AARD&period=max&api_key=YOUR_API_KEY